TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25781888

Group type: EXPERIMENTAL
Intervention: Guide with facilitation support through workshops for managers and ongoing support
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group conducting programs as usual
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 24696926

Group type: EXPERIMENTAL
Intervention: In‐dwelling catheter removed after 24 hours (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: In‐dwelling catheter removed after 72 hours (Group B)
Number of subjects: 100
Study: 20865457

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoro-popliteal block (US-FPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 40
Study: 18843961

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 1 g thrice daily during menstrual cycle days 1-5
Number of subjects: 131

Group type: COMPARATOR
Intervention: Norethisterone (NET) 5 mg twice daily on days 19-26
Number of subjects: 131
Study: 16849704

Group type: EXPERIMENTAL
Intervention: FreeStyle Flash
Number of subjects: 100

Group type: COMPARATOR
Intervention: One Touch Ultra
Number of subjects: 100
Study: 14690339

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Low number of cultured Malassezia yeasts
Number of subjects: 137
Study: 11737343

Group type: EXPERIMENTAL
Intervention: Concorde trial participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delta trial participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-enrolled participants
Number of subjects: 0
Study: 8695137

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.25 mg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 ug/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 ug/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 200
Study: 1627437

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CMFP) consisting of six 4-week cycles of cyclophosphamide (100 mg/m2 orally days 1-14), methotrexate (40 mg/m2 IV days 1 and 8), fluorouracil (600 mg/m2 IV days 1 and 8), and prednisone (40 mg/m2 orally days 1-14)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1191
Study: 6692322

Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tamoxifen after adrenalectomy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Adrenalectomy after tamoxifen
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Adrenalectomy (primary and secondary therapy)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tamoxifen (primary and secondary therapy)
Number of subjects: 51
Study: 31163337

Group type: EXPERIMENTAL
Intervention: Needle biopsy (performed in 969 patients, 33% of total)
Number of subjects: 2971

Group type: EXPERIMENTAL
Intervention: High-risk histology
Number of subjects: 2971

Group type: EXPERIMENTAL
Intervention: Age ≥ 2 years
Number of subjects: 2971

Group type: EXPERIMENTAL
Intervention: Preoperative tumour volume
Number of subjects: 2971
Study: 29335932

Group type: EXPERIMENTAL
Intervention: FORTA List (2015 version)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Delphi consensus validations
Number of subjects: 47
Study: 27283377

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 international units)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study: 25153936

Group type: EXPERIMENTAL
Intervention: Self-chosen relaxing music
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Self-chosen happy music
Number of subjects: 123

Group type: COMPARATOR
Intervention: Audio book
Number of subjects: 123

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 123
Study: 22581111

Group type: EXPERIMENTAL
Intervention: Green tea extract (379 mg daily for 3 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study: 20471761

Group type: EXPERIMENTAL
Intervention: Estrogen-only therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen-plus-progestin therapies
Number of subjects: 0
Study: 17872548

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy and referral to Gamblers Anonymous (GA)
Number of subjects: 231
Study: 15734179

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-directive supportive therapy (NST)
Number of subjects: 82
Study: 12135945

Group type: EXPERIMENTAL
Intervention: Transcoronary ablation of septal hypertrophy (TASH)
Number of subjects: 129
Study: 9949706

Group type: EXPERIMENTAL
Intervention: Testing at preferred (optimal) times of day
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Testing at nonpreferred (nonoptimal) times of day
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 316
Study: 7775344

Group type: COMPARATOR
Intervention: C
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: UC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: E
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ST
Number of subjects: 35
Study: 2253661

Group type: EXPERIMENTAL
Intervention: Budesonide 3.2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7361710

Group type: EXPERIMENTAL
Intervention: Invasive papillary cancer
Number of subjects: 35
Study: 31743238

Group type: EXPERIMENTAL
Intervention: Virtual PT (telerehabilitation with remote clinician oversight)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Virtual PT
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study: 31509953

Group type: EXPERIMENTAL
Intervention: High-dose protein regimen (scNPN)
Number of subjects: 274

Group type: COMPARATOR
Intervention: High-dose protein regimen (iNPN)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Standard-dose protein regimen (scNPN)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard-dose protein regimen (iNPN)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Weight gain (control groups only)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Head growth (intervention groups only)
Number of subjects: 274
Study: 27884388

Group type: COMPARATOR
Intervention: 100 ml contrast medium
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 75 ml contrast medium via bolus shaping
Number of subjects: 190
Study: 25958708

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Lung protective strategy ventilation (LPSV)
Number of subjects: 49
Study: 23890352

Group type: EXPERIMENTAL
Intervention: High protein (HP) diet (1.4 g protein∙kg(‐1)∙d(‐1))
Number of subjects: 88

Group type: COMPARATOR
Intervention: Normal protein (NP) diet (0.8 g protein∙kg(‐1)∙d(‐1))
Number of subjects: 88
Study: 22186252

Group type: EXPERIMENTAL
Intervention: Canine fossa puncture (CFP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) including middle meatus antrostomy (MMA)
Number of subjects: 110
Study: 18705668

Group type: EXPERIMENTAL
Intervention: Young-High
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elderly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Young-Low
Number of subjects: 0
Study: 16602255

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) administered at 2.4 or 2.0 atmospheres absolute, preceded the chemotherapy regimen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chemotherapy regimen (six intravenous pulses of cyclophosphamide 1000mg/m2, doxorubicin 50mg/m2, and vincristine 1.5mg/m2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chemotherapy regimen
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trial regime (HBO2 + chemotherapy)
Number of subjects: 32
Study: 12850387

Group type: EXPERIMENTAL
Intervention: Valsartan or amlodipine-based treatment
Number of subjects: 13449
Study: 10853722

Group type: EXPERIMENTAL
Intervention: Early supported discharge and continued rehabilitation at home by a specialized team
Number of subjects: 83

Group type: COMPARATOR
Intervention: Routine rehabilitation
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Home rehabilitation
Number of subjects: 83
Study: 10423633

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (60 microg/d intravenously)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buflomedil (150 mg/d intravenously)
Number of subjects: 20
Study: 8420016

Group type: EXPERIMENTAL
Intervention: Predictive dosing method
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physician dosing method
Number of subjects: 41

Group type: COMPARATOR
Intervention: Individual dosing method
Number of subjects: 41
Study: 3523328

Group type: EXPERIMENTAL
Intervention: Naproxen (500 to 1000 mg daily for five days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 25
Study: 31935151

Group type: EXPERIMENTAL
Intervention: Nordic Musculoskeletal Questionnaire (NMQ)
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Quick Exposure Check (QEC)
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Ergonomic working conditions checklist
Number of subjects: 1501
Study: 29979642

Group type: EXPERIMENTAL
Intervention: Outsmart HPV intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 27059951

Group type: EXPERIMENTAL
Intervention: PF‐06291874 (150 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐06291874 (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24720273

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment and clinical assessment
Number of subjects: 514

Group type: COMPARATOR
Intervention: Standard care (clinical assessment)
Number of subjects: 514
Study: 22212248

Group type: EXPERIMENTAL
Intervention: Standard prophylaxis (20-40 IU kg(‐1) every other day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic (PK)-tailored prophylaxis (20-80 IU kg(‐1) every third day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Any prophylaxis (standard or PK-tailored)
Number of subjects: 66
Study: 20826706

Group type: EXPERIMENTAL
Intervention: Repeated apneas
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rebreathing
Number of subjects: 10
Study: 18154942

Group type: EXPERIMENTAL
Intervention: Observation-only treatment condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Guided-observation treatment condition
Number of subjects: 36

Group type: COMPARATOR
Intervention: Instructed-observation treatment condition
Number of subjects: 36
Study: 16885104

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15252291

Group type: EXPERIMENTAL
Intervention: Naltrexone depot
Number of subjects: 315
Study: 11686823

Group type: EXPERIMENTAL
Intervention: 0.1% PVP-iodine
Number of subjects: 223

Group type: COMPARATOR
Intervention: Non-surgical therapy
Number of subjects: 223
Study: 9560747

Group type: EXPERIMENTAL
Intervention: Early atropine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional atropine administration
Number of subjects: 0
Study: 7875999

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Simvastatin and Control
Number of subjects: 70
Study: 3586567

Group type: EXPERIMENTAL
Intervention: tranexemic acid
Number of subjects: 76

Group type: COMPARATOR
Intervention: saline
Number of subjects: 76
Study: 30055974

Group type: EXPERIMENTAL
Intervention: Combination therapy with omega-3 fatty acids and acipimox
Number of subjects: 119

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 119
Study: 27034624

Group type: EXPERIMENTAL
Intervention: Thermogenic dietary supplement
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 26573936

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic (NLC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Rheumatologist-led clinic (RLC)
Number of subjects: 107
Study: 23496975

Group type: EXPERIMENTAL
Intervention: Special care units
Number of subjects: 358

Group type: COMPARATOR
Intervention: Open units
Number of subjects: 358
Study: 20870255

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (20 to 100U, max 300U, every 3 months if necessary)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conservative treatment (thiocolchicoside 16mg/day and physical rehabilitation)
Number of subjects: 38
Study: 18000469

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (>5.5 g/day)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 676
Study: 17141634

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cycle ergometer testing (RMT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 30
Study: 12707126

Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 48
Study: 11080460

Group type: EXPERIMENTAL
Intervention: Community-based model of midwifery providing continuity of care
Number of subjects: 0
Study: 8957948

Group type: EXPERIMENTAL
Intervention: Biofeedback training with laxatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (laxatives alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (biofeedback + laxatives and laxatives alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with abnormal behaviour scores who were successfully treated
Number of subjects: 0
Study: 10136830

Group type: COMPARATOR
Intervention: Oral advice from nurse on producing a sputum sample (114 patients)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Oral advice plus written instructions (110 patients)
Number of subjects: 224
Study: 3771955

Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle with high water-content meal (apple sauce)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle with dry meal (corn flakes and bread)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle taken 5 minutes before dry meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline administered intravenously
Number of subjects: 0
Study: 31774380

Group type: EXPERIMENTAL
Intervention: Vision Training (VT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No‐Vision Training (NVT)
Number of subjects: 24
Study: 29851784

Group type: EXPERIMENTAL
Intervention: Superficial parotidectomy and elective neck dissection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Elective neck dissection
Number of subjects: 100
Study: 27544428

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines totally self-applied
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with therapist guidance
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (both conditions)
Number of subjects: 57
Study: 24719394

Group type: EXPERIMENTAL
Intervention: Two-step irradiance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-dose 100 mg tramadol sustained-release tablets
Number of subjects: 0
Study: 22241810

Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care plus education (Control)
Number of subjects: 102
Study: 20363710

Group type: EXPERIMENTAL
Intervention: Yellow‐lens glasses to represent age‐related color vision changes
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 17534855

Group type: EXPERIMENTAL
Intervention: Prospective screening for HLA-B*5701
Number of subjects: 0
Study: 16006861

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy (TLA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic adrenalectomy (RLA)
Number of subjects: 57
Study: 12804844

Group type: EXPERIMENTAL
Intervention: Intranasal virosomal influenza vaccine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 127
Study: 10569658

Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg for the first 24 hours, with a possible repeated dose of 300 mg for 24 hours)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Amiodarone (30 mg/kg for the first 24 hours, with a possible repeated dose of 15 mg/kg for 24 hours)
Number of subjects: 86
Study: 8712137

Group type: EXPERIMENTAL
Intervention: Daily exercise and a low-fat diet according to the American Heart Association's recommendation phase III
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (usual care by private physician)
Number of subjects: 113
Study: 1682644

Group type: EXPERIMENTAL
Intervention: Misoprostol (200-600 micrograms)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Misoprostol (200-1000 micrograms) after 200 mg mifepristone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Misoprostol after mifepristone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 33
Study: 7184401

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pentazocine 30 mg
Number of subjects: 31
Study: 30908129

Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 743
Study: 29727332

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (capecitabine plus oxaliplatin)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 592
Study: 29051561

Group type: EXPERIMENTAL
Intervention: MAGT1-mediated disturbance of Mg2+ homeostasis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of HBV infection
Number of subjects: 0
Study: 27417980

Group type: EXPERIMENTAL
Intervention: Integrated, closed-loop feedback system with mobile health technology (mHealth) data on health behaviors and clinical recommendations
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard of care recommendations and weekly health behavior reports for self-guided care
Number of subjects: 68
Study: 24306460

Group type: EXPERIMENTAL
Intervention: Multilinguistic intervention with a phonological and orthographic awareness emphasis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multilinguistic intervention with an additional morphological awareness focus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 23047380

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Multiport laparoscopic cholecystectomy (MPLC)
Number of subjects: 54
Study: 19651267

Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 23-gauge needle
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pain intensity during injection (VAS)
Number of subjects: 77
Study: 17477785

Group type: EXPERIMENTAL
Intervention: Home-visit education and invitation intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (no home visit education)
Number of subjects: 304
Study: 15241909

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) in large cavities
Number of subjects: 151
Study: 11939159

Group type: EXPERIMENTAL
Intervention: GnRH agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 0
Study: 10719298

Group type: COMPARATOR
Intervention: BANS 256 microgram
Number of subjects: 217

Group type: COMPARATOR
Intervention: BANS 64 microgram
Number of subjects: 217

Group type: COMPARATOR
Intervention: BANS (both dosages)
Number of subjects: 217

Group type: COMPARATOR
Intervention: BANS
Number of subjects: 217
Study: 8633968

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transaxillary minithoracotomy (TAMT)
Number of subjects: 66
Study: 1289512

Group type: EXPERIMENTAL
Intervention: Atenolol (At) 50 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrendipine (Ni) 40 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20
Study: 6428425

Group type: EXPERIMENTAL
Intervention: tocainide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: propafenone
Number of subjects: 15
Study: 31172607

Group type: EXPERIMENTAL
Intervention: Xenogeneic block loaded with rhBMP‐2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Autogenous bone block
Number of subjects: 24
Study: 30091443

Group type: EXPERIMENTAL
Intervention: ERAS
Number of subjects: 62

Group type: COMPARATOR
Intervention: C
Number of subjects: 62
Study: 27103031

Group type: EXPERIMENTAL
Intervention: Bilateral 20 mL 0.3% ropivacaine and 2 mL dexmedetomidine (0.5 µg/kg) (group RD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral 20 mL 0.3% ropivacaine and 2 mL 0.9% normal saline (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (group R and group RD)
Number of subjects: 60
Study: 24901918

Group type: EXPERIMENTAL
Intervention: Progressive eccentric and concentric training for 12 weeks on the Monitorized Functional Squat System (MFSS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard rehabilitation protocol (control group)
Number of subjects: 33